Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hofseth Biocare Asa maintains 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units. This distribution indicates that each of the company's active matters is being reviewed by a different person in a different technical division of the USPTO.
The busiest examiner for the company is BOECKELMAN, JACOB A, who is currently managing 1 pending office action. This workload is distributed such that no single individual manages all 3 pending office actions. This means that no single examiner has a dominant role in the portfolio's current prosecution.
With 3 distinct art units involved, the company must navigate the specific examination guidelines of different technical divisions within the Biotechnology & Pharmaceuticals sector. The presence of 3 distinct examiners, including BOECKELMAN, JACOB A, suggests that the prosecution outcomes will depend on the individual interpretations of these separate officials.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| KIM, BRYAN | 1 | 28.4% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415498 | RESPIRATORY TREATMENTS USING SALMONID OIL COMPOSITIONS | BOECKELMAN, JACOB A | 22d |
| 16973749 | FISH PROTEIN HYDROLYSATE POWDER AND A COMPOSITION COMPRISING SAID POWDER FOR USE AS A MEDICAMENT | KIM, BRYAN | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18415498 | RESPIRATORY TREATMENTS USING SALMONID OIL COMPOSITIONS | BOECKELMAN, JACOB A | 22d |
| 16973749 | FISH PROTEIN HYDROLYSATE POWDER AND A COMPOSITION COMPRISING SAID POWDER FOR USE AS A MEDICAMENT | KIM, BRYAN | 33d |
| 18036382 | RESPIRATORY TREATMENTS | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1658 | 1 |
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18415498 | RESPIRATORY TREATMENTS USING SALMONID OIL COMPOSITIONS | BOECKELMAN, JACOB A | 1655 | §103§112 | Non-Final OA | 22d | Pending | Jan 17, 2024 |
| 18036382 | RESPIRATORY TREATMENTS | HIBBERT, CATHERINE S | 1658 | §102§112DP | Non-Final OA | — | Pending | May 10, 2023 |
| 16973749 | FISH PROTEIN HYDROLYSATE POWDER AND A COMPOSITION COMPRISING SAID POWDER FOR USE AS A MEDICAMENT | KIM, BRYAN | 1792 | §103 | Non-Final OA | 33d | Pending | Dec 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial